AFP and neoplasm: Early changes in tumor markers, AFP and des-gamma-carboxy prothrombin (DCP), after Dur/Tre introduction have been reported to be a useful biomarker for predicting objective response and clinical prognosis in Dur/Tre therapy [27,28].